CoChat

Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease

Hock, Christoph, Maddalena, Alessia, Raschig, Andreas, Müller-Spahn, Franz, Eschweiler, Gerhard, Huger, Klaus, Hewer, Isabella, Hampel, Harald, Müller-Thornsen, Thomas, Oertel, Wolfgang, Wienrich, Marion, Signorell, Andri, Gonzalez-agosti, Charo, Nitsch, Roger M. · 2003 · Amyloid
Cited by 112

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The amyloid beta-peptides A beta 40 and A beta 42 are highly amyloidogenic constituents of brain beta-amyloid plaques in Alzheimer's disease (AD). Lowering their formation may be achieved by modulating the activities of proteases that cleave the amyloid precursor protein (A beta PP), including alpha- beta-, and gamma-secretases. Talsaclidine is a functionally selective muscarinic m1 agonist that stimulates non-amyloidogenic alpha-secretase processing in vitro. We compared cerebrospinal fluid (CSF) levels of A beta 40 and A beta 42 measured by ELISA before and at the end of 4 weeks of treatment with talsaclidine. The medication was administered in a double-blind, placebo-controlled, and randomized clinical study to 40 patients with AD. Talsaclidine (n = 34) decreased CSF levels of A beta 42 by a median of 19% (p < 0.001) as compared to baseline. The mean difference between CSF levels of A beta 42 before and after treatment with talsaclidine (n = 34) was -46 +/- 73 (SD) pg/ml as compared to 0 +/- 8 (SD) pg/ml with placebo (n = 6) (p < 0.05). CSF levels of A beta 40 increased during treatment with placebo (n = 6) while they remained stable during treatment with talsaclidine (n = 31) (1.118 +/- 1.710 ng/ml, and -0.170 +/- 0.967 ng/ml, respectively; p < 0.05). These data show that treatment with the m1 agonist talsaclidine reduced A beta peptides, and particularly A beta 42, in AD patients, suggesting it as a potential amyloid lowering therapy of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/13506120308995249

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 112

Metadata

Authors
Hock, C., Maddalena, A., Raschig, A., Müller-Spahn, F., Eschweiler, G., Huger, K., Hewer, I., Hampel, H., Müller-Thornsen, T., Oertel, W., Wienrich, M., Signorell, A., Gonzalez-agosti, C., & Nitsch, R. M.
Venue
Amyloid
Published
2003-01
Volume
10
Issue
1
Pages
1-6
ISSN
  • 1350-6129 (ISSN-L)
  • 1744-2818
OpenAlex
W1971834278
Cited by
112
References
6
FWCI
4.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease. https://app.cochat.ai/papers/10.3109/13506120308995249
The paper
Hock, C., Maddalena, A., Raschig, A., Müller-Spahn, F., Eschweiler, G., Huger, K., Hewer, I., Hampel, H., Müller-Thornsen, T., Oertel, W., Wienrich, M., Signorell, A., Gonzalez-agosti, C., & Nitsch, R. M. (2003). Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease. Amyloid. https://doi.org/10.3109/13506120308995249

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.